EcoDrugPlus

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSEEEG00000015588
Gene Symbol: SRC
4 Cross references
191 Possible Orthologues:

Tek Tyrosine Kinase, Endothelial

Ensembl ID : ENSEEEG00000022277
Gene Symbol: TEK
4 Cross references
166 Possible Orthologues:

Udp-Glucose Ceramide Glucosyltransferase

Ensembl ID : ENSEEEG00000010771
Gene Symbol: UGCG
4 Cross references
212 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSEEEG00000009783
Gene Symbol: WEE1
4 Cross references
206 Possible Orthologues:

Wee1 G2 Checkpoint Kinase

Ensembl ID : ENSEEEG00000014747
Gene Symbol: WEE1
4 Cross references
141 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSEEEG00000001363
Gene Symbol: YES1
4 Cross references
146 Possible Orthologues:

Yes Proto-Oncogene 1, Src Family Tyrosine Kinase

Ensembl ID : ENSEEEG00000006803
Gene Symbol: YES1
4 Cross references
195 Possible Orthologues:

Acetylcholinesterase

Ensembl ID : ENSEEEG00000011796
Gene Symbol: ACHE
4 Cross references
234 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSEEEG00000008066
Gene Symbol: ACVR2B
4 Cross references
196 Possible Orthologues:

Activin A Receptor Type 2ba

Ensembl ID : ENSEEEG00000007373
Gene Symbol: ACVR2BA
2 Cross references
194 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSEEEG00000006939
Gene Symbol: ADORA1
4 Cross references
208 Possible Orthologues:

Adenosine A1 Receptor B

Ensembl ID : ENSEEEG00000001077
Gene Symbol: ADORA1B
4 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).